PRODH and cancer: After more than a decade of global interest in cancer cell metabolism and clinical development of small molecule metabolic and mitochondrial inhibitors as a novel class of anticancer drugs (Martinez-Outschoorn et al. 2017), pharmaceutical targeting of mitochondrial PRODH has only recently come into oncologic focus (Elia et al. 2017; Scott et al. 2019).